Manages central (cranial) diabetes insipidus. ANDA 210223, held by Ubi. Desmopressin Acetate.
As of Nov 21, 2026, ANDA 210223 (Desmopressin Acetate), held by Ubi, was first approved by FDA on Sep 17, 2020, with 1 approved supplement and 0 published complete response letters.
Desmopressin acetate injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Hemophilia A - for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 17, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desmopressin Acetate0.004MG/ML · injectable;injection | Desmopressin Acetate | Rx |
| Aug 27, 2025 | Supplement 5Manufacturing | Approved | None posted |
| Sep 17, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters